Page 9 - ஜார்ஜ்டவுன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theragnostics Strengthens Board of Directors with Key Appointments Drug Development Experts Dr Dennis Langer and Professor Ken Herrmann Appointed as Non-Executive Directors LONDON, Aug. 4, 2021 /PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board. Dr Dennis Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies, and has an extensive pharmaceutical company background. He previously served as CEO of Neose Technologies, Inc.; was President of Dr Reddy s North American business; and was Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a Director of the Whitehead Institute for Biomedical Research, Myriad Genetics, Inc. (NASDAQ: MYGN) and Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX). Dr La

United statesCity ofUnited kingdomIan gowrie smithPrnewswire theragnosticsDennis langerGreg mullenDrug development experts dr dennis langerUniversity of california los angelesHarvard law schoolWhitehead institute for biomedical researchBrooklyn immunotherapeutics incColumbia universityGenetics incGeorgetown university school of medicineDepartment of nuclear medicine at universit